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INTRODUCTION
Sertoli cells (SC), which constitute the structural frame-
work that support developing germ cells in the seminiferous
tubules, have been implicated as the major component of im-
mune privilege in the testis (1). In fact, ectopically transplant-
ed allogeneic SC survived and co-transplantation of allogeneic
islets with SC aggregates allowed long-term graft survival
without additional systemic immunosuppression in animal
models (2, 3). Also xenogeneic SC from neonatal pigs (NPSC)
were able to survive cell-mediated rejection when transplant-
ed as xenografts in nonimmunosuppressed rodents (4).
SC are known to express fas ligand (FasL) (5), transforming
growth factor (TGF)  1 (6), which are believed to be related
with immunoprotective, anti-inflammatory properties respec-
tively. However, high levels of FasL expression does not always
correlate with graft survival, as shown in pancreatic islet trans-
plantation models (7). FasL induces polymorphonuclear cell
(PMN) activation (8), and the inflammation can be modu-
lated by TGF 1 (9). But it is not clear whether the expres-
sion of FasL and TGF 1 qualify prolonged allograft survival.
In addition, SC produce clusterin, an amphipathic glyco-
protein, which has many anti-inflammatory activities and
have been shown to produce many immunoprotective factors
(10). As complement plays a dominant role in the process of
humoral immunity-mediated rejection, regulation of com-
plement activation may be related to the prolonged graft sur-
vival of SC. In fact, complement regulatory protein (CRP)
such as membrane cofactor protein (MCP), decay-accelerating
factor (DAF) and protectin (CD59) are known to be expressed
in the testis (11), but it is not clear whether SC produce CRP,
thus providing a microenvironment that may aid allograft
survival at non-privileged sites.
Our study was performed to test whether the expression of
FasL, TGF 1, and clusterin qualify prolonged allograft sur-
vival and to determine additional factors that may be related
to the prolonged survival of SC at non-privileged sites.
MATERIALS AND METHODS
Animals and cell lines
C57BL/6 female mice, aged 7 weeks, were purchased form
Orient Corporation (Korea) and used as recipients. All ani-
mal experiments were performed with approval of the Insti-
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Allo-transplanted Sertoli Cells
Sertoli cells (SC) are known to contain immunoprotective properties, which allow
them to survive as allografts without the use of immunosuppressive drugs. Experi-
ments were designed to determine which factors are related to prolonged survival
of allogeneic SC. Balb/c derived Sertoli (TM4) and colon cancer (CT-26) cell lines
were implanted beneath the kidney capsule of non-immunosuppressed C57BL/6
mice and compared their survival as allografts. Compared to TM4 graft, which sur-
vived more than 7 days after transplantation, CT-26 showed massive infiltration of
polymorphonuclear cells, necrosis and enlargement of draining lymph nodes. Cul-
tured cell lines showed no differences in their expression patterns of FasL, TGF 1,
clusterin and two complement regulatory proteins (CRP, i.e., membrane cofactor
protein, MCP; decay accelerating factor, DAF), but protectin (CD59), another mem-
ber of CRP was expressed only on TM4. These results suggest that CD59 and un-
known factors may contribute to the prolonged survival of SC in non-immunoprivi-
leged sites.
Key Words : Sertoli Cells; Fas Ligand; Transfroming Growth Factor Beta1; Clusterin; Complement Regulatory
Protein; CD59
Received : 7 June 2006
Accepted : 30 August 2006278 H.-M. Lee, B.C. Oh, D.-P. Lim, et al.
tutional Animal Care and Use Committee (IACUC) of Clin-
ical Research Institute in Seoul National University Hospi-
tal. And National Research Council (NRC) ‘Guidelines for
the Care and Use of Laboratory Animals’ were followed (re-
vised 1996).
Two Balb/c derived cell lines, TM-4 and CT-26 were used
as an allogeneic SC and control cells, respectively. The first
was established cell lines of non-tumorigenic SC (12) and
the latter is colon carcinoma. Both cell lines were obtained
from the Korea Cell line Bank (KCLB). TM4 was cultured
37℃, 5% CO2 incubator. Culture medium were 1:1 mix-
ture of Ham’s F12 medium and Dulbecco’s modified Eagle’s
Medium supplemented with 4.5 g/L glucose, 1.2 g/L sodi-
um bicarbonate and 15 mM HEPES, horse serum (5%), heat
inactivated fetal bovine serum (2.5%). CT-26 was cultured
in Dulbecco’s modified Eagle’s Medium supplemented with
heat inactivated fetal bovine serum (10%).
Implantation
C57BL/6 mice were anesthetized by intraperitoneal injec-
tion of ketamine-rumpon mixture and then transplanted with
5×106 cells respectively. Left kidney was exposed via trans-
verse abdominal incisions. Cells for implantation were har-
vested immediately prior to implantation, and the viability
and number of each cell line was determined. Each counted
cells were placed in yellow tips (Gilson), closed with paraf-
fin, pelleted by centrifugation, and gently placed under the
left renal subcapsular space after removing paraffin.
Histologic examination
Nephrectomies were performed for morphologic assess-
ment at post operation day (POD) 2 (n=3), 7 (n=3), and 15
(n=3). The graft-bearing kidneys were immersed in 4% para-
formaldehyde solution and embedded in paraffin. After depa-
raffinization and rehydration, tissue sections were stained
hematoxylin and eosin. Coded slides were examined by light
microscopy.
Flow cytometry
For analysis of T cell phenotype changes in draining lymph
node, lymphocytes from renal lymph node at 2, 7, 15 post-
transplant days were counted and evaluated for the expres-
sion of T cell activation markers. Briefly, cells were incubat-
ed with various fluorescence-labeled monoclonal antibody
(BD Pharmingen, San Diego, CA, U.S.A.) diluted at opti-
mal concentration for immunostaining. Immunoglobin G
block (2.4G2) were used to avoid the nonspecific binding to
Fc receptors. To determine the intracellular expression of
FasL and TGF 1 on cultured cells, 5×105 nonfixed single
cells before transplantation, intracellular staining was per-
formed using Cytofix/CytopermTM Plus (BD Pharmingen).
Briefly, the cells were harvested and washed twice in PBS,
and cytofix/cytoperm was added for 20 min at 4℃. The cells
were washed twice in perm/wash and resuspended in 100  L
of perm/wash. Biotinylated rat anti-TGF 1 or anti-FasL (BD
Pharmingen) was added at a dilution of 1:100 to each tube
and incubated for 30 min at 4℃. Subsequently washed twice
in perm/wash, Streptavidin-Fluorescein Isothiocyanate (BD
Pharmingen) was added at a dilution of 1:500 and incubat-
ed for 30 min at 4℃. After the final incubation, the cells
were washed twice in perm/wash, and the fluorescence was
measured on a FACS Caliber (BD Pharmingen).
RT-PCR
Total RNA was extracted using EazyBlue (Intron Biotech-
nology, Inc., Sungnam, Korea). All RNA samples were stored
at -80℃until reverse transcription. Briefly, total RNA (3  g)
was reverse transcribed in 20  L, using 200 U recombinant
M-MLV Reverse Transcriptase (Bioneer Corp., Daejeon, Korea),
20 U RNAsin (Invitrogen Corp., San Diego, CA, U.S.A.), 5
mM each dNTP mix (Intron Biotechnology Inc.), 100 pMol
oligo dT18VN (COSMO Co. Ltd, Korea), and 10 mM of
dithiothreitol for 1 hr at 42℃. All samples were reverse tran-
scribed using the same master mix to minimize nonspecific
differences.
Semi-quantitative reverse transcriptase-polymerase chain
reaction (RT-PCR) was performed using a DNA thermal cycler
(PTC0200 DNA Engine, MJ Research Inc., Waltham, MA,
U.S.A.). cDNA (2.5  L) was amplified in a 50- L reaction
volume containing; 1 mM dNTPs, 2 mM MgCl2, 10 pMol
primers, 2.5 U Taq (Intron Biotechnology Inc.), and reaction
buffer (supplied with enzyme) using the following conditions;
94℃ (5 min) hot start followed by 35 amplification cycles
of; 94℃(45 sec), 51 to 60℃(45-60 sec), and 72℃(45 sec).
The nucleotide sequences and annealing temperatures of the
primer pairs were as follows: FasL (56.5℃) 5′ -GCC CAT
GAA TTA CCC ATG TC-3′ and 5′ -GTT CTG CCA GTT
CCT TCT GC-3′(326 bp); TGF 1 (55℃) 5′ -GCT CAC
TAC TCT GGA TAC GG-3′ and 5′ -ATC CAC ACA GAC
AAC TTT CC-3′ (466 bp); clusterin (55.4℃) 5′ -CAG TTC
CCA GAC GTG GAT TT-3′ and 5′ -TGA GGT GTT GAG
CAT CTT CG-3′ (267 bp) ; MCP (52℃) 5′ -GCC CTT CTG
TTT CTG CTG TC-3′ and 5′ -CCA AAC GAA GGG TCC
TGT AA-3′ (257 bp); DAF (52℃) 5′ -CCC ACC TCC AGA
CAT TCC TA-3′ and 5′ -TGG GAG TGG AGG TTG TTT
TC-3′(310 bp); CD59 (55℃) 5′ -CAG TCA CTG GCG
ATC TGA AA-3′ and 5′ -AGA TTC AAA ATG GCC ACC
AG-3′(427 bp); GAPDH (54.3℃) 5′ -AAC TTT GGC
ATT GTG GAA GG-3′ and 5′ -ACA CAT TGG GGG TAG
GAA CA-3′ (223 bp). PCR products were run in 1.5% aga-
rose gels containing ethidium bromide staining (0.5  g/mL)
and photographed under UV light. The sizes of PCR prod-
ucts were verified against 100-bp ladders (Bioneer Corp.).Complement Regulatory Protein and Sertoli Cells 279
RESULTS
Graft survival
Cells implanted under the kidney capsule of immunocom-
petent C57BL/6 mice were determinded macro- and micro-
scopically to ascertain whether they could survive as an allo-
geneic grafts. Macroscopically, cellular grafts were easily iden-
tifiable at POD 2 and POD 7, but not at POD 15. To fur-
ther confirm the survival of grafts, tissue sections were exam-
ined histologically (Fig. 1, 2). Histological examination of
graft-bearing kidneys was performed by hematoxylin-eosin
staining to detect the presence of transplanted cells. On a spec-
imen taken at POD 2, abundant grafted cells were detected
under the kidney capsule of both groups and overlying the
kidney, whereas kidney capsules of CT-26 transplant, har-
vested at POD 7, revealed an extensive lymphocytic infiltra-
tion and central necrosis (Fig. 2C, D). Whereas the compos-
ite allografts from animals of TM4 transplant demonstrated
a relatively small number of lymphocytes (Fig. 2A, B). At
POD 15, there was no implanted cells identified in either
groups.
Changes of T cell phenotype in draining lymph node
Macroscopically, renal lymph nodes from CT-26 transplant
were more distended than TM4 transplant and revealed a
time-dependent increase of lymphocyte numbers, 6 times at
POD 2, 12 times at POD 7 (data not shown). Flow cytomet-
ric analysis for CD4+CD44+ T cell populations in the drain-
ing lymph node showed an early increase up to POD 7 and
decreased gradually thereafter. CD4+CD62L+ T cells showed
a marked increase at POD 15 in both groups. But there were
no differences in the percentage of T cell phenotype between
two groups (data not shown).
Characteristics of TM4 and CT-26
To compare the characteristics of the two cell lines, we eval-
uated the expression of FasL, TGF 1 and clusterin using flow-
cytometry and RT-PCR. As shown in Fig. 3, there were no
remarkable differences in the expression of FasL and TGF 1.
RT-PCR analysis for FasL and TGF 1 paralleded the result
of FACS analyses (Fig. 4). The expression of clusterin mRNA
was relatively high in CT-26 cells compared to TM4. Altho-
ugh further analysis is required for verification whether the
Fig. 1. Photomicrographs of allografts stained with hematoxylin and eosin at POD 2. Abundant grafted cells were detected under the kid-
ney capsule of both groups (A and B, TM4; C and D, CT-26) and overlying the kidney. There are few lymphocyte infiltration (arrows). Origi-
nal magnification×40 (A and C) and ×200 (B and D).
A B
C D280 H.-M. Lee, B.C. Oh, D.-P. Lim, et al.
mRNA expression of these molecules are effectively trans-
lated into protein during immune attack and secreted as
soluble factors, these results suggest that the expression of
theses molecules do not qualify the prolonged allogeneic SC
survival.
Complement regulatory proteins
To identify a possible mechanism related to prolonged
survival of allogeneic cellular graft, both cell lines were exam-
ined for the expression of complement regulatory proteins
i.e., MCP, DAF, CD59. Interestingly mRNA of CD46 and
DAF were not detected in both cell lines but the expression
of CD59 mRNA were detected only in TM4 (Fig. 4). These
results suggest that the expression of CD59 may contribute
Fig. 2. Photomicrographs of allografts stained with hematoxylin and eosin at POD 7. There are focal infiltration of lymphocytes in TM4 grafts
(A and B), whereas the CT-26 graft shows PMN infiltration and central necrosis (C and D). Arrows indicate infiltrated lymphocytes and
PMN. Original magnification ×40 (A and C) and ×200 (B and D).
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Fig. 3. Expressions of FasL (upper panel) and TGF 1 (lower pa-
nel) in cultured cell lines. FACS analysis shows the similar expres-
sion of FasL and TGF 1. Control analyses (thin line) involve only
the fluorescent secondary antibody.
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Fig. 4. RT-PCR analysis of mRNA expression in cultured cell lines.
Each lane shows the mRNA expression in TM4 (T), CT-26 (C), and
control (mouse testis, Ctl). There were no remarkable differences
in the expression of FasL, TGF 1, MCP, and DAF. Clusterin ex-
pression shows relatively high in CT-26. Of interest, CD59 mRNA
was expressed only in TM4.to the allogeneic SC survival.
DISCUSSION
Our results showed that complement regulatory protein,
CD59, may be related to the prolonged survival of allogeneic
SC at non-immunoprivileged sites. TM4 showed prolonged
survival compared to CT-26 (Fig. 1, 2). TM-4, implanted
beneath the kidney capsule of immunocompetent B6 mice,
showed negligible histologic changes at least up to 7 days
after implantation compared to CT-26, which showed severe
PMN infiltration and necrosis at same time points. But these
two cell lines showed similar expression of FasL, TGF 1 and
clusterin on FACS analyses and RT-PCR (Fig. 3, 4). Also there
was no difference in T cell subpopulations from draining lym-
ph nodes at each time point, and the higher number of lym-
phocyte from renal lymph node in the CT-26 transplanted
group suggests that TM4 may have certain immune-modu-
lating mechanisms that can delay the rejection from host
immune response. It has been shown that immune privilege
may be maintained partially by the local production and
release of immunosuppressive cytokines (13) and neuropep-
tides (14). In fact, SC are known to secrete unidentified fac-
tors that decrease IL-2 production (15) and T cell prolifera-
tion (16).
Fas-FasL interactions are known to be an important mech-
anism for the maintenance of immune privilege and have
been implicated as a form of peripheral tolerance (18), but
it was not proven as a mediator of the protective effects of
SC in our experiment. Previous reports suggested that TGF1
from SC modulates cell activity and favors Th2 over Th1 cell
differentiation (19). However, considering the same expres-
sion of TGF 1 in both cell line (Fig. 3, 4), this phenomenon
might be caused not only by TGF 1 but also by other un-
known factors. Also the concept of immune privilege as defined
in terms of expressions of clusterin that prolong the survival
of allogeneic grafts were not applied to CT-26.
On the other hand, several soluble factors including neuro-
peptide such as vasoactive intestinal peptide and alpha mela-
nocyte stimulating hormone and glucocorticoids, have been
implicated in the maintenance of immune privilege (20). SC
provide numerous factors required for the orderly develop-
ment and protection of spermatozoa and germ cells from
immune attacks by synthesizing and secreting factors that
may lead to local immune tolerance (15, 17). It is possible
that one of the many functions of SC in testis is to secret com-
plement inhibitors, which coat the spermatozoa and protect
them from complement lysis. Humoral immunity-mediat-
ed graft rejection occurs when natural antibodies bind allo-
antigens located on the surface of target cells, resulting in
the activation of the enzymatic cascade via the classical path-
way leading to formation of the membrane attack complex
(MAC) and cellular lysis. This can be overcome by over-exp-
ression in the donor, CRP such as MCP, DAF, and CD59. As
complement plays a dominant role in the process of humoral
immunity-mediated rejection, the regulation of complement
activation is required to overcome graft rejection. In the ab-
sence of these proteins, C3 convertase of both the classical
and alternative pathways as well as MAC would be deposit-
ed, leading to graft damage. In fact, inhibition of graft rejec-
tion has been achieved using the transgenic approach with
varying success rates, depending on the experimental model
(21, 22). Our first (to our knowledge) identification of CD59
expression on SC suggests that a regulatory system exists to
protect SC from humoral immunity-mediated graft destruc-
tion by complement activation.
In summary, our results suggest that expressions of CD59
may contribute to the survival of allogeneic SC and immune
privileged microvironment may not be guaranteed just by
the expression of FasL, TGF 1, or clusterin. Further studies
on the immunoprotective factors produced by SC may iden-
tify novel mechanisms including immune modulatory pro-
teins that may provide clues for promoting local tolerogenic
environment.
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